Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.

Carla Ripamonti1, Elena Fagnoni, Tiziana Campa

  • 1Rehabilitation and Palliative Care Operative Unit, National Cancer Institute of Milan, Via Venezian, 1, Milan, Italy. carla.ripamonti@istitutotumori.mi.it

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|September 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating PSMA PET into urological practice: insights from a multidisciplinary Italian survey.

Minerva urology and nephrology·2026
Same author

Surgical Approach to Liver Metastasis from Gastroenteropancreatic Neuroendocrine Tumors in the Era of Precision Oncology.

Cancers·2026
Same author

<sup>177</sup>Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

Expert review of anticancer therapy·2026
Same author

Investigation of MicroRNAs as predictors of radioligand therapy response in gastroenteropancreatic neuroendocrine tumours.

Scientific reports·2026
Same author

The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion.

Advances in therapy·2025
Same author

AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.

European journal of nuclear medicine and molecular imaging·2025

Samarium-153 lexidronam effectively reduced pain intensity in patients with prostate cancer and bone metastases. This treatment also decreased analgesic drug consumption, offering a safe option for pain management.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Pain Management

Background:

  • Bone metastases in prostate cancer frequently cause significant pain, impacting patient quality of life.
  • Pain on movement is a particularly challenging aspect of bone metastasis management.
  • Current treatments for painful bone metastases often have limitations or side effects.

Purpose of the Study:

  • To evaluate the efficacy of a single dose of samarium-153 (153-Sm) lexidronam in managing pain intensity in patients with prostate cancer and bone metastases.
  • To assess the reduction in analgesic drug consumption following 153-Sm lexidronam treatment.
  • To observe variations in pain at rest and on movement post-treatment.

Main Methods:

  • A case series design was employed.

Related Experiment Videos

  • Thirteen patients with hormone-refractory prostate cancer and painful bone metastases received a single dose of 1.0 mCi/kg of 153-Sm lexidronam.
  • Pain intensity was assessed using a verbal scale at rest and during movement, with analgesic drug consumption monitored for 4 weeks post-infusion.

    • Main Results:

    • Over 60% of patients experienced a significant decrease in pain intensity on movement, and over 50% reported improvement in pain at rest.
    • A substantial reduction in analgesic drug use was observed in most patients treated with 153-Sm lexidronam.
    • Bone marrow toxicity was mild and reversible in a small subset of patients.

    Conclusions:

    • Samarium-153 lexidronam demonstrates effectiveness in alleviating pain associated with bone metastases in prostate cancer patients, both at rest and during movement.
    • The treatment offers a safe and effective therapeutic option for managing pain in this patient population.
    • Further research may explore optimal dosing and long-term outcomes.